Literature DB >> 29888484

Sample size calculation for studies with grouped survival data.

Zhiguo Li1, Xiaofei Wang1, Yuan Wu1, Kouros Owzar1.   

Abstract

Grouped survival data arise often in studies where the disease status is assessed at regular visits to clinic. The time to the event of interest can only be determined to be between two adjacent visits or is right censored at one visit. In data analysis, replacing the survival time with the endpoint or midpoint of the grouping interval leads to biased estimators of the effect size in group comparisons. Prentice and Gloeckler developed a maximum likelihood estimator for the proportional hazards model with grouped survival data and the method has been widely applied. Previous work on sample size calculation for designing studies with grouped data is based on either the exponential distribution assumption or the approximation of variance under the alternative with variance under the null. Motivated by studies in HIV trials, cancer trials and in vitro experiments to study drug toxicity, we develop a sample size formula for studies with grouped survival endpoints that use the method of Prentice and Gloeckler for comparing two arms under the proportional hazards assumption. We do not impose any distributional assumptions, nor do we use any approximation of variance of the test statistic. The sample size formula only requires estimates of the hazard ratio and survival probabilities of the event time of interest and the censoring time at the endpoints of the grouping intervals for one of the two arms. The formula is shown to perform well in a simulation study and its application is illustrated in the three motivating examples.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  grouped survival data; proportional hazards model; sample size calculation

Mesh:

Year:  2018        PMID: 29888484      PMCID: PMC6262878          DOI: 10.1002/sim.7847

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Designing follow-up intervals.

Authors:  G M Raab; J A Davies; A B Salter
Journal:  Stat Med       Date:  2004-10-30       Impact factor: 2.373

2.  Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.

Authors:  Zhiguo Li; Peter Gilbert; Bin Nan
Journal:  Biometrics       Date:  2008-12       Impact factor: 2.571

3.  Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined.

Authors:  E D Saad; A Katz
Journal:  Ann Oncol       Date:  2008-12-18       Impact factor: 32.976

4.  Power of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model.

Authors:  John M Lachin
Journal:  Stat Med       Date:  2012-07-16       Impact factor: 2.373

5.  Sample size calculation in cost-effectiveness cluster randomized trials: optimal and maximin approaches.

Authors:  Md Abu Manju; Math J J M Candel; Martijn P F Berger
Journal:  Stat Med       Date:  2014-07-10       Impact factor: 2.373

6.  Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.

Authors:  Uchenna O Njiaju; Eric R Gamazon; Lidija K Gorsic; Shannon M Delaney; Heather E Wheeler; Hae Kyung Im; M Eileen Dolan
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

7.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

8.  Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).

Authors:  Maria Q Baggstrom; Mark A Socinski; Xiaofei F Wang; Lin Gu; Thomas E Stinchcombe; Martin J Edelman; Sherman Baker; Josephine Feliciano; Paul Novotny; Olwen Hahn; Jeffrey A Crawford; Everett E Vokes
Journal:  J Thorac Oncol       Date:  2017-02-01       Impact factor: 15.609

Review 9.  Endpoints for assessing drug activity in clinical trials.

Authors:  Richard Pazdur
Journal:  Oncologist       Date:  2008

10.  Misspecification of Cox regression models with composite endpoints.

Authors:  Longyang Wu; Richard J Cook
Journal:  Stat Med       Date:  2012-06-27       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.